NCT02473016View on ClinicalTrials.gov

Nasal Carbon Dioxide for the Symptomatic Treatment of Classical Trigeminal Neuralgia

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

March 31, 2017

Study Completion Date

April 30, 2017

Conditions
Trigeminal Neuralgia
Interventions
DRUG

Carbon Dioxide Drug Delivery System (CDDS)

Doses will be administered to the nostril on the side of the trigeminal episode \[ipsilateral nostril\].

Trial Locations (6)

10032

Columbia University Medical Center, New York

15213

University of Pittsbugh Medical Center (UPMC), Pittsburgh

22903

University of Virginia, Charlottesville

29425

Medical University of South Carolina (MUSC), Charleston

33634

Meridien Research, Tampa

90095

University of California, Los Angeles (UCLA), Los Angeles

All Listed Sponsors
lead

Capnia, Inc.

INDUSTRY

NCT02473016 - Nasal Carbon Dioxide for the Symptomatic Treatment of Classical Trigeminal Neuralgia | Biotech Hunter | Biotech Hunter